Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 308

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

A novel antibiotic class targeting the lipopolysaccharide transporter

Open access
Zampaloni, Claudia, Mattei, Patrizio, Bleicher, Konrad, Winther, Lotte, Thäte, Claudia, Bucher, Christian, Adam, Jean-Michel, Alanine, Alexander, Amrein, Kurt E., Baidin, Vadim, Bieniossek, Christoph, Bissantz, Caterina, Boess, Franziska, Cantrill, Carina, Clairfeuille, Thomas, Dey, Fabian, Di Giorgio, Patrick, du Castel, Pauline, Dylus, David, Dzygiel, Pawel, Felici, Antonio, García-Alcalde, Fernando, Haldimann, Andreas, Leipner, Matthew, Leyn, Semen, Louvel, Séverine, Misson, Pauline, Osterman, Andrei, Pahil, Karanbir, Rigo, Sébastien, Schäublin, Adrian, Scharf, Sebastian, Schmitz, Petra, Stoll, Theodor, Trauner, Andrej, Zoffmann, Sannah, Kahne, Daniel, Young, John A. T., Lobritz, Michael A., Bradley, Kenneth A.·2024·Nature

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global pathogen with limited treatment options 1. No new antibiotic chemical class with activity against A. baumannii has reached patients in over 50 years 1. Here we report the identification and optimization of tethered macrocyclic peptide (MCP) antibiotics with potent antibacterial activity against CRAB. The mechanism of action of this molecule class involves blocking the transport of bacterial lipopolysaccharide from the inner membrane to its destination on the outer membrane, through inhibition of the LptB 2 FGC complex. A clinical candidate derived from the MCP class, zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms. This chemical class represents a promising treatment paradigm for patients with invasive infections due to CRAB, for whom current treatment options are inadequate, and additionally identifies LptB 2 FGC as a tractable target for antimicrobial drug development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-023-06873-0

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 308

Metadata

Authors
Zampaloni, C., Mattei, P., Bleicher, K., Winther, L., Thäte, C., Bucher, C., Adam, J.-M., Alanine, A., Amrein, K. E., Baidin, V., Bieniossek, C., Bissantz, C., Boess, F., Cantrill, C., Clairfeuille, T., Dey, F., Di Giorgio, P., du Castel, P., Dylus, D., Dzygiel, P., Felici, A., García-Alcalde, F., Haldimann, A., Leipner, M., Leyn, S., Louvel, S., Misson, P., Osterman, A., Pahil, K., Rigo, S., Schäublin, A., Scharf, S., Schmitz, P., Stoll, T., Trauner, A., Zoffmann, S., Kahne, D., Young, J. A. T., Lobritz, M. A., & Bradley, K. A.
Venue
Nature
Published
2024-01-03
Volume
625
Issue
7995
Pages
566-571
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4390570560
Cited by
308
References
54
FWCI
32.51
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A novel antibiotic class targeting the lipopolysaccharide transporter. https://app.cochat.ai/papers/10.1038/s41586-023-06873-0
The paper
Zampaloni, C., Mattei, P., Bleicher, K., Winther, L., Thäte, C., Bucher, C., Adam, J.-M., Alanine, A., Amrein, K. E., Baidin, V., Bieniossek, C., Bissantz, C., Boess, F., Cantrill, C., Clairfeuille, T., Dey, F., Di Giorgio, P., du Castel, P., Dylus, D., . . . Bradley, K. A. (2024). A novel antibiotic class targeting the lipopolysaccharide transporter. Nature. https://doi.org/10.1038/s41586-023-06873-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.